ABRAM’S CLINICAL DRUG THERAPY RATIONALES FOR
xx xx xx xx xx
NURSING PRACTICE 13th EDITION GERALYN FRANDSEN’S
xx xx xx xx xx
TESTBANK/COMPLETE GUIDE 2024-2025/ALL CHAPTERS 1-61
xx xx xx xx xx
,Chapter 1: The Foundation of Pharmacology: Quality and Safety
xx xx xx xx xx xx xx xx
1. A xxpatient xxdiagnosed xxwith xxobsessive–compulsive xxdisorder xxhas xxbeen
xxprescribed xxoralp x aroxetine xxhydrochloride. xxWhat x x is xxthe xxexpected
xxeffect xx for xxthis xxprescription?
A. Curative xxeffect xxon xxsymptoms
B. Systemic xxeffect xxon xxsymptoms
C. Local xxeffect xxon xxsymptoms
D. Parenteral xxeffect xxon xxsymptoms
ACCURATE xxANSWER:-B
REASONING:->>>Pharmaceutical xxdrug xxthat xxproduce xxsystemic xxeffects xxare
xxtaken xxinto xxthe xxbody, xxcirculated xxthrough xxthe xxbloodstream xxto xxtheir xxsites xxof
xxaction xxin xxvarious xxbody xxtissues, xxand xxeventually xxeliminated xxfrom xxthe xxbody.
xxCurative xxagents xxare xxgiven xxto xxcure xxa xxdisease xxprocess. xxInx
this xxcase,
xxparoxetine xxhydrochloride xxwill xxcontrol xxthe xxsymptoms xxbut xxnot xxcure xxthe
xxdisorder.
Pharmaceutical xxdrug xxwith xxlocal xxeffects, xxsuch xxas xxsunscreen xxand xxlocal
xxanesthetics, xxact xx mainly xxat xxthe xxsite x
of xxapplication. xxParoxetine xxhydrochloride
xxis xxnot xxadministered xxparenterally. xxParenteral xxagents xare xxadministered
xxsubcutaneously, x x intramuscularly, xx or xxintravenously.
POINTS: 1 REFERENCE: p. xx3, xxIntroduction OBJ:
1
NAT: xxHospital xxclient xxNeeds: xxPhysiological xxIntegrity: xxPharmacological
xxand xxParenteral xxTherapiesx TOP: Chapter: xx1: xxThe xxFoundation xxof
xxPharmacology: xxQuality xxand xx Safety
KEY: x x Integrated xxProcess: xxNursing xxProcess
BLM: x x Cognitive xxLevel: xxUnderstand NOT: x x Multiple xxChoice
2. A xxhospital xxclient xxhas xxbeen xxprescribed xxan xxantibiotic. xxThis
xxpharmaceutical xxdrug xxis xxa xxnaturally xxoccurring s x ubstance xxthat xxhas
xxbeen xxche m ic al ly mod if ied. Wha t i xxs xx xxanother xxname xxfor xxthis xx type
G R A D E S B OO S T .C O M xx xx
xxof xxpharmaceutical xxdrug?
A. Synthetic xxdrug
B. Semisynthetic xxdrug
C. Biotechnology xxdrug
D. Prototype xxdrug
ACCURATE xxANSWER:-B
REASONING:->>>Semisynthetic xxpharmaceutical xxdrug xx(e.g., xxmany
xxantibiotics) xxare xxnaturally xxoccurring xxsubstances xxthat xxhave xxbeen xxchemically
xxmodified. xxSynthetic xxpharmaceutical xxdrug xxare xxmore xxstandardized xxin xxtheir
xxchemical xxcharacteristics, xxmore xxconsistent xxin xxtheir xxeffects, xxand xxless xxlikely
xxto xxproduce xxallergic xxreactions. xxBiotechnology xxpharmaceutical xxdrug xxinvolve
xxmanipulating xxDNAx and xxRNA xxand xxrecombining xxgenes xxinto xxhybrid
xxmolecules xxthat xxcan xxbe xxinserted xxinto xxliving xxorganisms. xxPrototype
xx pharmaceutical xxdrug xxare xxthe xxfirst xxdrug xxof xxa xxparticular xxgroup xxto xxbe
xxdeveloped.
POINTS: 1 REFERENCE: p. xx3, xxDrug xxSources OBJ:
1
NAT: xxHospital xxclient xxNeeds: xxPhysiological xxIntegrity: xxPharmacological
xxand xxParenteral xxTherapiesx
TOP: Chapter: xx1: xxThe xxFoundation xxof
, Pharmacology: xxQuality xxand xxSafety
xx
KEY: x x Integrated xxProcess: xxNursing xxProcess
BLM: x x Cognitive xxLevel: xxUnderstand NOT: xx Multiple xxChoice
3. Which xxclassification xxapplies xxto xxmorphine?
A. Central xxnervous xxsystem xxdepressant
B. Central xxnervous xxsystem xxstimulant
, C. Anti-inflammatory
D. Antihypertensive
ACCURATE xxANSWER:-A
REASONING:->>>Pharmaceutical xxdrug xxare xxclassified xxaccording xxto xxtheir
xxeffects xxon xxparticular xxbody xxsystems, xxtheir xxtherapeutic xxuses, xxand xxtheir
xxchemical xxcharacteristics. xxMorphine xxis xxclassified xxas xxa xxcentral xxnervous
xxsystem xxdepressant xxand xxwill xxproduce xxthis xxeffect xxin xxthe xxhospital xxclient. xxA
central xxnervous xxsystem xxstimulant xxincreases xxattention xxand xxraises xxmood. xxAn
x
xxanti-inflammatoryx agent xxdecreases xxinflammation xxat xxthe xxsite xxof xxtissue xxor xxjoint
xxinflammation. xxAn xxantihypertensivex agent xxreduces xxblood xxpressure.
POINTS: 1 REFERENCE: p. xx3, xxDrug
xxClassifications xxand xxPrototypesO
x BJ: 1
NAT: xxHospital xxclient xxNeeds: xxPhysiological xxIntegrity: xxPharmacological
xxand xxParenteral xxTherapiesx TOP: Chapter: xx1: xxThe xxFoundation xxof
xxPharmacology: xxQuality xxand xxSafety
KEY: x x Integrated xxProcess: xxNursing xxProcess
BLM: x x Cognitive xxLevel: xxRemember NOT: x x Multiple xxChoice
4. A xxhospital xxclient xxis xxadministered xxamoxicillin. xxThe xxgeneric xxname xxof xxthis
xxpharmaceutical xxdrug xxbelongs xxto xxwhichd x rug xxgroup?
A. Selective xxserotonin xxreuptake xxinhibitors
B. Diuretics
C. Penicillins
D. ACE xxinhibitors
ACCURATE xxANSWER:-C
REASONING:->>>The xxgeneric xxname xxoften xxindicates xxthe xxdrug xxgroup xx(e.g.,
xxpharmaceutical xxdrug
GRADESBOOST.CO
with xxgeneric xxnames xxending xxin xx“cillin” xxare xxpenicillins). xxSelective
xxserotonin xxreuptakex inhibitors xxare xxpharmaceutical xxdrugs
that xxhave xxantidepressant xxeffects; xxSSRI xxis xxa xxbroad xxclassification, xxnot xxa xxgeneric
xxname. xxDiureticsx are xxpharmaceutical xxdrugs xxthat xxincrease xxurine xxoutput;
xxdiuretic xxis xxa xxbroad xxclassification, xxnot xxa xxgeneric xxname. xxACE xxinhibitor xxis
xxthe xxbroad xxclassification xxfor xxthe xxangiotensin xxreceptor xxblockers, xxnot xxthex generic
xx name.
POINTS: 1 REFERENCE: p. xx3, xxDrug xxNames OBJ:
2
NAT: xxHospital xxclient xxNeeds: xxPhysiological xxIntegrity: xxPharmacological
xxand xxParenteral xxTherapiesx TOP: Chapter: xx1: xxThe xxFoundation xxof
xxPharmacology: xxQuality xxand xxSafety
KEY: x x Integrated xxProcess: xxNursing xxProcess
BLM: x x Cognitive xxLevel: xxUnderstand NOT: x x Multiple xxChoice
5. The xxadministration xxof xxdiphenhydramine xxis xxregulated xxby xxwhich xxU.S. xxgovernment
xx agency?
A. Public xxHealth xxService
B. Federal xxTrade xxCommission
C. Occupational xxSafety xxand xxHealth xxAdministration
D. Food xxand
xx Drug
xx xx xx xx xx
NURSING PRACTICE 13th EDITION GERALYN FRANDSEN’S
xx xx xx xx xx
TESTBANK/COMPLETE GUIDE 2024-2025/ALL CHAPTERS 1-61
xx xx xx xx xx
,Chapter 1: The Foundation of Pharmacology: Quality and Safety
xx xx xx xx xx xx xx xx
1. A xxpatient xxdiagnosed xxwith xxobsessive–compulsive xxdisorder xxhas xxbeen
xxprescribed xxoralp x aroxetine xxhydrochloride. xxWhat x x is xxthe xxexpected
xxeffect xx for xxthis xxprescription?
A. Curative xxeffect xxon xxsymptoms
B. Systemic xxeffect xxon xxsymptoms
C. Local xxeffect xxon xxsymptoms
D. Parenteral xxeffect xxon xxsymptoms
ACCURATE xxANSWER:-B
REASONING:->>>Pharmaceutical xxdrug xxthat xxproduce xxsystemic xxeffects xxare
xxtaken xxinto xxthe xxbody, xxcirculated xxthrough xxthe xxbloodstream xxto xxtheir xxsites xxof
xxaction xxin xxvarious xxbody xxtissues, xxand xxeventually xxeliminated xxfrom xxthe xxbody.
xxCurative xxagents xxare xxgiven xxto xxcure xxa xxdisease xxprocess. xxInx
this xxcase,
xxparoxetine xxhydrochloride xxwill xxcontrol xxthe xxsymptoms xxbut xxnot xxcure xxthe
xxdisorder.
Pharmaceutical xxdrug xxwith xxlocal xxeffects, xxsuch xxas xxsunscreen xxand xxlocal
xxanesthetics, xxact xx mainly xxat xxthe xxsite x
of xxapplication. xxParoxetine xxhydrochloride
xxis xxnot xxadministered xxparenterally. xxParenteral xxagents xare xxadministered
xxsubcutaneously, x x intramuscularly, xx or xxintravenously.
POINTS: 1 REFERENCE: p. xx3, xxIntroduction OBJ:
1
NAT: xxHospital xxclient xxNeeds: xxPhysiological xxIntegrity: xxPharmacological
xxand xxParenteral xxTherapiesx TOP: Chapter: xx1: xxThe xxFoundation xxof
xxPharmacology: xxQuality xxand xx Safety
KEY: x x Integrated xxProcess: xxNursing xxProcess
BLM: x x Cognitive xxLevel: xxUnderstand NOT: x x Multiple xxChoice
2. A xxhospital xxclient xxhas xxbeen xxprescribed xxan xxantibiotic. xxThis
xxpharmaceutical xxdrug xxis xxa xxnaturally xxoccurring s x ubstance xxthat xxhas
xxbeen xxche m ic al ly mod if ied. Wha t i xxs xx xxanother xxname xxfor xxthis xx type
G R A D E S B OO S T .C O M xx xx
xxof xxpharmaceutical xxdrug?
A. Synthetic xxdrug
B. Semisynthetic xxdrug
C. Biotechnology xxdrug
D. Prototype xxdrug
ACCURATE xxANSWER:-B
REASONING:->>>Semisynthetic xxpharmaceutical xxdrug xx(e.g., xxmany
xxantibiotics) xxare xxnaturally xxoccurring xxsubstances xxthat xxhave xxbeen xxchemically
xxmodified. xxSynthetic xxpharmaceutical xxdrug xxare xxmore xxstandardized xxin xxtheir
xxchemical xxcharacteristics, xxmore xxconsistent xxin xxtheir xxeffects, xxand xxless xxlikely
xxto xxproduce xxallergic xxreactions. xxBiotechnology xxpharmaceutical xxdrug xxinvolve
xxmanipulating xxDNAx and xxRNA xxand xxrecombining xxgenes xxinto xxhybrid
xxmolecules xxthat xxcan xxbe xxinserted xxinto xxliving xxorganisms. xxPrototype
xx pharmaceutical xxdrug xxare xxthe xxfirst xxdrug xxof xxa xxparticular xxgroup xxto xxbe
xxdeveloped.
POINTS: 1 REFERENCE: p. xx3, xxDrug xxSources OBJ:
1
NAT: xxHospital xxclient xxNeeds: xxPhysiological xxIntegrity: xxPharmacological
xxand xxParenteral xxTherapiesx
TOP: Chapter: xx1: xxThe xxFoundation xxof
, Pharmacology: xxQuality xxand xxSafety
xx
KEY: x x Integrated xxProcess: xxNursing xxProcess
BLM: x x Cognitive xxLevel: xxUnderstand NOT: xx Multiple xxChoice
3. Which xxclassification xxapplies xxto xxmorphine?
A. Central xxnervous xxsystem xxdepressant
B. Central xxnervous xxsystem xxstimulant
, C. Anti-inflammatory
D. Antihypertensive
ACCURATE xxANSWER:-A
REASONING:->>>Pharmaceutical xxdrug xxare xxclassified xxaccording xxto xxtheir
xxeffects xxon xxparticular xxbody xxsystems, xxtheir xxtherapeutic xxuses, xxand xxtheir
xxchemical xxcharacteristics. xxMorphine xxis xxclassified xxas xxa xxcentral xxnervous
xxsystem xxdepressant xxand xxwill xxproduce xxthis xxeffect xxin xxthe xxhospital xxclient. xxA
central xxnervous xxsystem xxstimulant xxincreases xxattention xxand xxraises xxmood. xxAn
x
xxanti-inflammatoryx agent xxdecreases xxinflammation xxat xxthe xxsite xxof xxtissue xxor xxjoint
xxinflammation. xxAn xxantihypertensivex agent xxreduces xxblood xxpressure.
POINTS: 1 REFERENCE: p. xx3, xxDrug
xxClassifications xxand xxPrototypesO
x BJ: 1
NAT: xxHospital xxclient xxNeeds: xxPhysiological xxIntegrity: xxPharmacological
xxand xxParenteral xxTherapiesx TOP: Chapter: xx1: xxThe xxFoundation xxof
xxPharmacology: xxQuality xxand xxSafety
KEY: x x Integrated xxProcess: xxNursing xxProcess
BLM: x x Cognitive xxLevel: xxRemember NOT: x x Multiple xxChoice
4. A xxhospital xxclient xxis xxadministered xxamoxicillin. xxThe xxgeneric xxname xxof xxthis
xxpharmaceutical xxdrug xxbelongs xxto xxwhichd x rug xxgroup?
A. Selective xxserotonin xxreuptake xxinhibitors
B. Diuretics
C. Penicillins
D. ACE xxinhibitors
ACCURATE xxANSWER:-C
REASONING:->>>The xxgeneric xxname xxoften xxindicates xxthe xxdrug xxgroup xx(e.g.,
xxpharmaceutical xxdrug
GRADESBOOST.CO
with xxgeneric xxnames xxending xxin xx“cillin” xxare xxpenicillins). xxSelective
xxserotonin xxreuptakex inhibitors xxare xxpharmaceutical xxdrugs
that xxhave xxantidepressant xxeffects; xxSSRI xxis xxa xxbroad xxclassification, xxnot xxa xxgeneric
xxname. xxDiureticsx are xxpharmaceutical xxdrugs xxthat xxincrease xxurine xxoutput;
xxdiuretic xxis xxa xxbroad xxclassification, xxnot xxa xxgeneric xxname. xxACE xxinhibitor xxis
xxthe xxbroad xxclassification xxfor xxthe xxangiotensin xxreceptor xxblockers, xxnot xxthex generic
xx name.
POINTS: 1 REFERENCE: p. xx3, xxDrug xxNames OBJ:
2
NAT: xxHospital xxclient xxNeeds: xxPhysiological xxIntegrity: xxPharmacological
xxand xxParenteral xxTherapiesx TOP: Chapter: xx1: xxThe xxFoundation xxof
xxPharmacology: xxQuality xxand xxSafety
KEY: x x Integrated xxProcess: xxNursing xxProcess
BLM: x x Cognitive xxLevel: xxUnderstand NOT: x x Multiple xxChoice
5. The xxadministration xxof xxdiphenhydramine xxis xxregulated xxby xxwhich xxU.S. xxgovernment
xx agency?
A. Public xxHealth xxService
B. Federal xxTrade xxCommission
C. Occupational xxSafety xxand xxHealth xxAdministration
D. Food xxand
xx Drug
